Randomized trial · people

SS-31: walk distance rose with dose in 5-day MMPOWER trial

Checked against the paper Randomized trialPublished by PepVault

The takeaway

An early, short trial in adults with primary mitochondrial myopathy found walking distance improved with higher intravenous doses of elamipretide, without added safety concerns over 5 days. Larger, longer trials are still needed.

Kind
Randomized trial
Studied in
People
Number studied
36
Published
2018
Journal
Neurology

What they tested

The team tested whether elamipretide (SS-31) is safe and improves exercise ability in adults with primary mitochondrial myopathy, a muscle disease confirmed by genetic testing in this trial.

How the study was done

A phase I/II, multicenter, randomized, double-blind, placebo-controlled trial in 36 adults with genetically confirmed primary mitochondrial myopathy. Participants got elamipretide into a vein at 0.01, 0.1 or 0.25 mg/kg/h, or placebo (a dummy infusion), for 2 hours in a dose-escalating order. The main measure was the 6-minute walk test (how far a person walks in 6 minutes) after 5 days.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

People in the highest-dose arm walked an average of 64.5 m farther at day 5, compared with 20.4 m farther in the placebo group (p = 0.053). Walk distance rose with dose across the elamipretide arms (p = 0.014). After adjusting for other factors that could affect results, the change was 51.2 m for the highest dose vs 3.0 m for placebo (p = 0.0297). No significant differences showed up in the other efficacy measures or in safety.

What it doesn’t show

This was a small trial with only 5 days of treatment, so it can't show longer-term benefit or safety. Elamipretide was given into a vein, and the other measures, such as exercise testing, symptoms and blood and urine markers, showed no significant change.

The paper

Karaa et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018.

The compound

More studies on SS-31

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo